Urinary tract infection (UTI treatment) is the infection of the lower or upper urinary tract and occurs due to colonization of microbial pathogen in the bladder or kidneys. The symptoms of UTI treatment are pain with urination, frequent urination and urination feeling despite having an empty bladder. UTI is more common in women as compared to men as their urethra is comparatively smaller. There are two types of urinary tract infections: complicated urinary tract infection and uncomplicated urinary tract infection.
The urinary tract infection treatment market majorly consists of the players such Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway and DuPont Nutrition & Biosciences among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Allergan and F. Hoffmann La-Roche Ltd. – Notable Market Players in Urinary Tract Infection Treatment Market
Below is the list of the growth strategies done by the players operating in the urinary tract infection treatment market:
| Year | News |
| March, 2017 | Pfizer launched Zavicefta (ceftazidime-avibactam) in the U.K. and Germany, a new antibiotic to treat complicated infections caused by Gram-negative bacteria. Pfizer expects to launch Zavicefta in additional markets outside the U.S. throughout 2017 and 2018 |
| April, 2019 | Teva Pharmaceutical Industries Ltd announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. |
| February, 2020 | Cipla USA Inc., a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, announced the acquisition of the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. |
